Jenoptik AG (JEN)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 37.44 |
|---|---|
| 52-week range | 18.15 – 48.42 |
| Return, 1 month / 3 months | −11.4% / −4.8% |
| Return, 1 year / 3 years | +89.5% / +91.5% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 44 |
| Volatility (1 year) | 50.6% |
| Worst drawdown (1 year) | -26.5% |
| Average daily value traded | 4.78M EUR |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Jenoptik is a German photonics company based in Jena. It develops and makes optical systems, laser processing machines and industrial metrology equipment, along with traffic monitoring systems and components for medical and semiconductor applications. Its customers are mainly industrial manufacturers and public authorities, with automotive, semiconductor, medical technology and defence among the markets it serves. The company combines optics, precision mechanics and electronics in its products and supplies them to customers in Germany and abroad.
On this site Jenoptik AG appears as a stock on the XETRA Stock Exchange (Germany), code JEN, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Jenoptik AG (JEN) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 37.44 on 23 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 236 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 89.5% and over the last three months it fell 4.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 4.4% | ||
| From 52-week high | -21.6% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -4.8% | ||
| 6-month return | 11.3% | ||
| 12-month return, skipping the last month | 113.8% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 50.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.5% | ||
| Liquidity | 85 · Strong | Trades actively. | |
| Average daily value traded | 4.78M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 34 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.2% |
|---|---|
| 1 month | −11.4% |
| 3 months | −4.8% |
| 6 months | +11.3% |
| 1 year | +89.5% |
| 3 years | +91.5% |
| 5 years | +24.2% |
Signals
| 50-day / 200-day average | 39.84 / 35.86 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.93 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Jun 2026 | EUR 0.4000 |
| 13 Jun 2025 | EUR 0.3800 |
| 19 Jun 2024 | EUR 0.3500 |
| 8 Jun 2023 | EUR 0.3000 |
| 16 Jun 2022 | EUR 0.2500 |
| 10 Jun 2021 | EUR 0.2500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.